Alvarez RD - Search Results

1

Conditionally replicative adenoviruses for ovarian cancer therapy.

Barnes MN, Coolidge CJ, Hemminki A, Alvarez RD, Curiel DT. Barnes MN, et al. Among authors: alvarez rd. Mol Cancer Ther. 2002 Apr;1(6):435-9. Mol Cancer Ther. 2002. PMID: 12477056 Review.

2

Gene therapy.

Huh WK, Barnes MN, Kelley FJ, Alvarez RD. Huh WK, et al. Among authors: alvarez rd. Cancer Treat Res. 2002;107:133-57. doi: 10.1007/978-1-4757-3587-1_6. Cancer Treat Res. 2002. PMID: 11775448 Review. No abstract available.

3

Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells.

Kanerva A, Mikheeva GV, Krasnykh V, Coolidge CJ, Lam JT, Mahasreshti PJ, Barker SD, Straughn M, Barnes MN, Alvarez RD, Hemminki A, Curiel DT. Kanerva A, et al. Among authors: alvarez rd. Clin Cancer Res. 2002 Jan;8(1):275-80. Clin Cancer Res. 2002. PMID: 11801569

4

Treatment of ovarian cancer with a tropism modified oncolytic adenovirus.

Bauerschmitz GJ, Lam JT, Kanerva A, Suzuki K, Nettelbeck DM, Dmitriev I, Krasnykh V, Mikheeva GV, Barnes MN, Alvarez RD, Dall P, Alemany R, Curiel DT, Hemminki A. Bauerschmitz GJ, et al. Among authors: alvarez rd. Cancer Res. 2002 Mar 1;62(5):1266-70. Cancer Res. 2002. PMID: 11888888

5

Adenoviruses in oncology: a viable option?

Hemminki A, Alvarez RD. Hemminki A, et al. Among authors: alvarez rd. BioDrugs. 2002;16(2):77-87. doi: 10.2165/00063030-200216020-00001. BioDrugs. 2002. PMID: 11985481 Review.

6

In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.

Hemminki A, Zinn KR, Liu B, Chaudhuri TR, Desmond RA, Rogers BE, Barnes MN, Alvarez RD, Curiel DT. Hemminki A, et al. Among authors: alvarez rd. J Natl Cancer Inst. 2002 May 15;94(10):741-9. doi: 10.1093/jnci/94.10.741. J Natl Cancer Inst. 2002. PMID: 12011224

7

Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses.

Kanerva A, Wang M, Bauerschmitz GJ, Lam JT, Desmond RA, Bhoola SM, Barnes MN, Alvarez RD, Siegal GP, Curiel DT, Hemminki A. Kanerva A, et al. Among authors: alvarez rd. Mol Ther. 2002 Jun;5(6):695-704. doi: 10.1006/mthe.2002.0599. Mol Ther. 2002. PMID: 12027553 Free article.

8

Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy.

Hemminki A, Wang M, Desmond RA, Strong TV, Alvarez RD, Curiel DT. Hemminki A, et al. Among authors: alvarez rd. Hum Gene Ther. 2002 Aug 10;13(12):1505-14. doi: 10.1089/10430340260185139. Hum Gene Ther. 2002. PMID: 12215271 Clinical Trial. No abstract available.

9

Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.

Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT. Hemminki A, et al. Among authors: alvarez rd. Cancer Res. 2003 Feb 15;63(4):847-53. Cancer Res. 2003. PMID: 12591736

10

The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy.

Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, Rivera AA, Bhoola SM, Barnes MN, Alvarez RD, Curiel DT, Hemminki A. Barker SD, et al. Among authors: alvarez rd. J Gene Med. 2003 Apr;5(4):300-10. doi: 10.1002/jgm.341. J Gene Med. 2003. PMID: 12692864

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters